Piper Sandler Downgrades Marker Therapeutics (MRKR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts MRKR Hot Sheet
Price: $0.98 +8.89%
Rating Summary:
9 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
9 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Piper Sandler analyst Edward A. Tenthoff downgraded Marker Therapeutics (NASDAQ: MRKR) from Overweight to Neutral with a price target of $2.50 (from $5.00).
For an analyst ratings summary and ratings history on Marker Therapeutics click here. For more ratings news on Marker Therapeutics click here.
Shares of Marker Therapeutics closed at $2.48 yesterday.
You May Also Be Interested In
- Hagerty Inc. (HGTY) PT Raised to $20 at Oppenheimer
- BMO Capital Downgrades Arthur J. Gallagher (AJG) to Market Perform, 'Taking Profits'
- DigitalOcean (DOCN) PT Lowered to $130 at Stifel
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
